Prognosis and Follow‐Up Recommendations for Subcutaneous and Dermal Leiomyosarcoma: Local Recurrence, Metastasis, and Overall Survival in a Danish Nationwide Cohort of 661 Patients

Grade 2 and 3 subcutaneous leiomyosarcoma should be classified as a high-risk sarcoma with a substantial risk of metastasis and poor overall survival, necessitating follow-up that includes both clinical examinations and PET/CT or CT of the thorax for 5 years to detect both locoregional and distant metastases. Dermal leiomyosarcoma should be considered a low-risk sarcoma due to its low risk of metastasis and moderate risk of local recurrence, suggesting that the follow-up can focus on clinical examinations for 4 years as the 10-year risk of local recurrence is < 1% after this time point.

Authors

Institutions

Publication Details

Journal
Journal of Surgical Oncology
Published
2025-09-18
DOI
https://doi.org/10.1002/jso.70095
Primary Topic
Sarcoma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Prognosis and Follow‐Up Recommendations for Subcutaneous and Dermal Leiomyosarcoma: Local Recurrence, Metastasis, and Overall Survival in a Danish Nationwide Cohort of 661 Patients

Thomas Mentzel, Mathias Ørholt, Anne Lene Wagenblast, David Hebbelstrup Jensen et al.
Journal of Surgical Oncology
Sarcoma Diagnosis and Treatment
article

Prognosis and Follow‐Up Recommendations for Subcutaneous and Dermal Leiomyosarcoma: Local Recurrence, Metastasis, and Overall Survival in a Danish Nationwide Cohort of 661 Patients

Thomas Mentzel, Mathias Ørholt, Anne Lene Wagenblast, David Hebbelstrup Jensen, Kiya Abebe, Søren Daugaard, Mikkel Herly, Erik Eiler Frydshou Bak, Andreas Haahr Larsen, Michael Mørk Petersen, Peter Vester‐Glowinski, Jason L. Hornick, Anand C. Loya, Grethe Schmidt
article en

Abstract

Grade 2 and 3 subcutaneous leiomyosarcoma should be classified as a high-risk sarcoma with a substantial risk of metastasis and poor overall survival, necessitating follow-up that includes both clinical examinations and PET/CT or CT of the thorax for 5 years to detect both locoregional and distant metastases. Dermal leiomyosarcoma should be considered a low-risk sarcoma due to its low risk of metastasis and moderate risk of local recurrence, suggesting that the follow-up can focus on clinical examinations for 4 years as the 10-year risk of local recurrence is < 1% after this time point.

Journal of Surgical OncologyVol. 132(6)
University of Copenhagen (DK), Brigham and Women's Hospital (US), Harvard University (US), University of Freiburg (DE), Odense University Hospital (DK), Copenhagen University Hospital (DK), Rigshospitalet (DK)
Albert-Ludwigs-Universität Freiburg, Gentofte Hospital, Odense Universitetshospital, Rigshospitalet
Openalex Percentile: Top 63%
Sarcoma Diagnosis and Treatment
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.